Diaxonhit Share Price Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 | 130M 141M 11.17B | Sales 2024 * | 138M 149M 11.86B | Capitalization | 148M 160M 12.74B |
---|---|---|---|---|---|
Net income 2023 | 4M 4.33M 344M | Net income 2024 * | 9M 9.74M 774M | EV / Sales 2023 | 1.29 x |
Net Debt 2023 * | 23M 24.89M 1.98B | Net cash position 2024 * | 9.9M 10.71M 851M | EV / Sales 2024 * | 1 x |
P/E ratio 2023 |
38.3
x | P/E ratio 2024 * |
15.3
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.3% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director of Finance/CFO | 43 | 30/09/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director/Board Member | 68 | 03/11/09 | |
Director/Board Member | 67 | 14/06/17 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |